Inflammatory breast cancer after neoadjuvant chemotherapy: Can magnetic resonance imaging precisely diagnose the final pathological response?

Annals of Surgical Oncology

Volumn 15, Issue 12, 2008, Pages 3609-3613

  Chen, J H ^a,b   Mehta, R S ^c   Nalcioglu, O ^a   Su, M Y ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; AGED; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; DIAGNOSTIC ACCURACY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; INFLAMMATORY DISEASE; LETTER; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; RETROSPECTIVE STUDY; TUMOR VOLUME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; NEOADJUVANT THERAPY; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 58149293809     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-008-0141-6     Document Type: Letter

References (29)

1. M Cariati TM Bennett-Britton SE Pinder 2005 "Inflammatory" breast cancer Surg Oncol 14 133 43
2. Walshe JM, Swain SM. Clinical aspects of inflammatory breast cancer. Breast Dis 2005-2006;22:35-44
3. GS Radunsky KL van Golen 2005 The current understanding of the molecular determinants of inflammatory breast cancer metastasis Clin Exp Metastasis 22 615 20
4. Wu M, Merajver SD. Molecular biology of inflammatory breast cancer: applications to diagnosis, prognosis, and therapy. Breast Dis 2005-2006;22:25-34
5. KW Hance WF Anderson SS Devesa 2005 Trends in inflammatory breast carcinoma incidence and survival: the Surveillance, Epidemiology, and End Results Program at the National Cancer Institute J Natl Cancer Inst 97 966 75
6. M Cristofanilli V Valero AU Buzdar 2007 Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease Cancer 110 1436 44
7. S Dawood M Cristofanilli 2007 What progress have we made in managing inflammatory breast cancer? Oncology (Williston Park) 21 673 9
8. Yang CH, Cristofanilli M. Systemic treatments for inflammatory breast cancer. Breast Dis 2005-2006;22:55-65
9. K Yasumura K Ogawa H Ishikawa 1997 Inflammatory carcinoma of the breast: characteristic findings of MR imaging Breast Cancer 4 161 9
10. WT Yang HT Le-Petross H Macapinlac 2008 Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings Breast Cancer Res Treat 109 417 26
11. S Chaturvedi C McLaren AC Schofield 2005 Patterns of local and distant disease relapse in patients with breast cancer treated with primary chemotherapy: do patients with a complete pathological response differ from those with residual tumour in the breast? Breast Cancer Res Treat 93 151 8
12. KN Ogston ID Miller S Payne 2003 A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival Breast 12 320 7
13. S Cleator M Parton M Dowsett 2002 The biology of neoadjuvant chemotherapy for breast cancer Endocr Relat Cancer 9 183 95
14. AH Honkoop PJ van Diest JS de Jong 1998 Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer Br J Cancer 77 621 6
15. V Ozmen N Cabioglu A Igci 2003 Inflammatory breast cancer: results of antracycline-based neoadjuvant chemotherapy Breast J 9 79 85
16. H Bonnefoi S Diebold-Berger P Therasse 2003 Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5-year clinical outcome? Ann Oncol 14 406 13
17. C Veyret C Levy P Chollet 2006 Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy: ten-year results from the French Adjuvant Study Group GETIS 02 Trial Cancer 107 2535 44
18. Ellis GK, Green SJ, Russell CA, et al. SWOG 0012, a randomized phase III comparison of standard doxorubicin (A) and cyclophosphamide (C) followed by weekly paclitaxel (T) versus weekly doxorubicin and daily oral cyclophosphamide plus G-CSF (G) followed by weekly paclitaxel as neoadjuvant therapy for inflammatory and locally advanced breast cancer. J Clin Oncol 2006;24:18S(Suppl):LBA537
19. JH Chen B Feig G Agrawal 2008 MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy Cancer 112 17 26
20. C Mazouni F Peintinger S Wan-Kau 2007 Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome J Clin Oncol 25 2650 5
21. JR Gralow HJ Burstein W Wood 2008 Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease J Clin Oncol 26 814 9
22. HM Kuerer LA Newman TL Smith 1999 Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy J Clin Oncol 17 460 9
23. TA Buchholz A Katz EA Strom 2002 Pathologic tumor size and lymph node status predict for different rates of locoregional recurrence after mastectomy for breast cancer patients treated with neoadjuvant versus adjuvant chemotherapy Int J Radiat Oncol Biol Phys 53 880 8
24. L Martincich F Montemurro GD Rosa 2004 Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging Breast Cancer Res Treat 83 67 76
25. L Martincich F Montemurro S Cirillo 2003 Role of Magnetic Resonance Imaging in the prediction of tumor response in patients with locally advanced breast cancer receiving neoadjuvant chemo-therapy Radiol Med (Torino) 106 51 8
26. A Rieber HJ Brambs A Gabelmann 2002 Breast MRI for monitoring response of primary breast cancer to neo-adjuvant chemotherapy Eur Radiol 12 1711 9
27. RM Warren LG Bobrow HM Earl 2004 Can breast MRI help in the management of women with breast cancer treated by neoadjuvant chemotherapy? Br J Cancer 90 1349 60
28. Kell MR, Morrow M. Surgical aspects of inflammatory breast cancer. Breast Dis 2005-2006;22:67-73
29. MG Lê R Arriagada G Contesso 2005 Dermal lymphatic emboli in inflammatory and non-inflammatory breast cancer: a French-Tunisian joint study in 337 patients Clin Breast Cancer 6 439 45